Friedman Richard J
Department of Orthopaedic Surgery, Roper Hospital, Charleston Orthopaedic Associates, 1012 Physicians Drive, Charleston, SC 29414, USA.
Thrombosis. 2010;2010:280731. doi: 10.1155/2010/280731. Epub 2010 Jul 29.
Anticoagulant drugs reduce the risk of venous thromboembolic events after total hip and knee arthroplasty. However, the use of current drugs, such as low molecular weight heparins, is hampered by their subcutaneous route of administration. The use of vitamin K antagonists is hampered by the requirement for routine coagulation monitoring and dose titration to provide effective anticoagulation without an increased risk of bleeding and numerous food and drug interactions. Clearly, there is a need for new oral, fixed-dose anticoagulant drugs that do not require coagulation monitoring, while demonstrating similar or better efficacy and safety profiles when compared with current agents.
抗凝药物可降低全髋关节和膝关节置换术后静脉血栓栓塞事件的风险。然而，目前的药物，如低分子量肝素，由于其皮下给药途径而受到限制。维生素K拮抗剂的使用则受到常规凝血监测和剂量滴定要求的限制，以提供有效的抗凝作用，同时又不增加出血风险以及避免众多食物和药物相互作用。显然，需要新型口服固定剂量抗凝药物，这类药物无需凝血监测，同时与现有药物相比，具有相似或更好的疗效和安全性。
